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Introduction
There were 8.8 million new cases and almost 1.5 million deaths 
from tuberculosis (TB) in 2010.1 While global TB incidence, death 
rates and prevalence are falling, new strategies are required if the 
Stop TB partnership targets are to be achieved.1 Developing a new 
vaccine is one key strategy. The existing TB vaccine, Mycobacterium 
bovis Bacille Calmette Guèrin (BCG) is cost-effective in preventing 
The safety and immunogenicity of a new candidate tuberculosis (TB) vaccine, Fp85a was evaluated alone and in 
heterologous prime-boost regimes with another candidate TB vaccine, MVa85a. This was an open label, non-controlled, 
non-randomized phase I clinical trial. Healthy previously BcG-vaccinated adult subjects were enrolled sequentially 
into three groups and vaccinated with Fp85a alone, or both Fp85a and MVa85a, with a four week interval between 
vaccinations. passive and active data on adverse events were collected. Immunogenicity was evaluated by enzyme Linked 
Immunospot (eLIspot), flow cytometry and enzyme Linked Immunosorbent assay (eLIsa). Most adverse events were 
mild and there were no vaccine-related serious adverse events. Fp85a vaccination did not enhance antigen 85a-specific 
cellular immunity. When MVa85a vaccination was preceded by Fp85a vaccination, cellular immune responses were lower 
compared with when MVa85a vaccination was the first immunisation. MVa85a vaccination, but not Fp85a vaccination, 
induced anti-MVa IgG antibodies. Both MVa85a and Fp85a vaccinations induced anti-Fp9 IgG antibodies. In conclusion, 
Fp85a vaccination was well tolerated but did not induce antigen-specific cellular immune responses. We hypothesize 
that Fp85a induced anti-Fp9 IgG antibodies with cross-reactivity for MVa85a, which may have mediated inhibition of the 
immune response to subsequent MVa85a. clinicalTrials.gov identification number: NcT00653770.
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severe disease in childhood, but prevention of adult pulmonary 
disease is inconsistent.2,3 Additionally, BCG is contraindicated in 
people infected with HIV due to the risk of disseminated BCG 
disease.4 Our approach is to develop a new vaccine regime to boost 
BCG, retaining BCG’s effectiveness in infants, while improving 
protection against adult pulmonary disease.
Antigen-specific T cell responses are a central requirement 
of vaccine-induced protection against TB. CD4+ T cells are 
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BCG-vaccinated healthy human subjects in heterologous prime-
boost regimes with MVA85A. Primary outcomes were passively 
and actively collected adverse event (AE) data of vaccine safety. 
Secondary outcomes were the cellular immunogenicity (mag-
nitude of antigen-specific T cell responses) of vaccinations, 
evaluated by ex-vivo interferon gamma (IFNγ) Enzyme Linked 
Immunospot (ELISpot) assay. In addition, cryopreserved samples 
were stored for further exploratory immunology assays, includ-
ing analysis of soluble cytokines within the first week after 
vaccination.
Results
Participant flow and recruitment. Between July 2007 and 
January 2009, 44 subjects were screened and 31 healthy adults 
enrolled (Fig. 1). All participants completed follow up by January 
2010. Recruitment ended before the planned sample size of 36 
subjects had been enrolled, as it was not possible to extend the 
expiry date for FP85A.
Baseline data. There were 12 subjects each in Group 1 and 
Group 2 and seven subjects in Group 3 (Table 1). More females 
essential, but not sufficient, for protective immunity against 
Mycobacterium tuberculosis (M.tb) and CD8+ T cells are also 
important.5 Recombinant viral vectors, such as poxviruses, are a 
particularly effective way of boosting pre-existing T cell responses, 
when used in heterologous prime-boost strategies. Clinical tri-
als of candidate malaria vaccines suggest improved boosting of 
antigen specific CD8+ T cells following vaccination with two 
heterologous recombinant poxvirus vectors.6 We have developed 
two non-replicating recombinant poxvirus-vectored candidate 
vaccines, Modified Vaccinia virus Ankara (MVA) and Fowlpox 
virus (FP9), each encoding mycobacterial antigen 85A (85A) and 
named MVA85A and FP85A respectively. MVA85A has been 
evaluated in several clinical trials since 2002 and induces a high 
frequency of CD4+ T cells and modest CD8+ T cell responses 
in healthy and HIV and M.tb -infected human subjects in the 
UK and Africa.7-16 FP85A has not previously been evaluated 
in human subjects. Vaccinating guinea pigs sequentially with 
BCG, MVA85A and FP85A enhanced protection against M.tb-
challenge compared with vaccination with BCG alone.17
Here, we present the results of the first clinical trial evalu-
ating the safety and immunogenicity of FP85A vaccination of 
Figure 1. cONsORT flow diagram, shows the flow of subjects through the trial. subjects were not randomized, but allocated sequentially into Group 1, 
then Group 2, then Group 3, in order of enrolment. all enrolled subjects completed follow up.
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MVA85A vaccination in Group 3 were mild and there were 
no SAEs.
Vaccine immunogenicity determined by ex-vivo IFNγ 
ELISpot. The kinetics and magnitude of the antigen-specific 
T cell responses to stimulation with 85A peptides following 
FP85A and MVA85A vaccination were assessed by ex-vivo IFNγ 
ELISpot assay.
After FP85A vaccination in Group 1, 85A responses did not 
increase compared with baseline levels at screening (Fig. 2A, 
Table 3A).
In Group 2, MVA85A vaccination expanded 85A-specific 
IFNγ-secreting T cells, which peaked at week one and were still 
maintained above baseline at week 52 (Fig. 2A and Table 3A). 
The magnitude of responses was comparable to those reported 
in previously published trials of MVA85A in BCG-vaccinated 
healthy adults (data not shown).15,16 After subsequent FP85A vac-
cination at week four, responses were not boosted, but continued 
to fall from the peak at week one.
In Group 3, 85A responses peaked at week five, one week after 
MVA85A vaccination. Responses declined to pre-vaccination lev-
els after week eight (Fig. 2A). The magnitude of responses to 
MVA85A in Group 3, when MVA85A was preceded by FP85A, 
was significantly lower compared with responses in Group 2 
(Table 3B).
Evaluation of soluble Th1 cytokines in the first week after 
vaccination. In Group 1, serum IFNγ, tumor necrosis factor α 
(TNFα) and interleukin 8 (IL-8) were not detected either before 
or within seven days of FP85A vaccination (Fig. 2B). In Group 2, 
IL-8 was detected in all subjects’ serum samples seven days after 
MVA85A vaccination and remained detectable in three subjects’ 
serum samples at week four (day 28). One week after FP85A 
vaccination, IL-8 was only detectable in one subjects’ serum. In 
Group 3, none of the cytokines were detectable one week after 
FP85A vaccination. IL-8 was detectable on the day of MVA85A 
vaccination and all three cytokines were detected in one subject’s 
serum sample one week after MVA85A vaccination.
Anti-vector studies. Responses to CD4+and CD8+T cell epitopes 
in Vaccinia and MVA. Responses to Vaccinia CD4+ and CD8+ T 
than males were enrolled. Group 1 had a lower proportion of 
male subjects than Groups 2 and 3. The ages of subjects and pre-
vaccination mycobacterial exposure were comparable between 
groups (Table 1).
Safety evaluation. Group 1. Following vaccination with 
FP85A, all subjects developed a local reaction comprising ery-
thema and induration, followed by scaling (dry, peeling skin) 
(Table 2). Most subjects also reported mild vaccine-site tender-
ness and pruritus. Moderate feverish symptoms, associated with a 
body temperature of 37.7°C, were recorded on the day of FP85A 
vaccination by one subject. All other systemic AEs after FP85A 
vaccination in Group 1 were mild.
One serious AE (SAE) occurred in a subject in Group 1 
(FP85A) during the time course of the trial, but was not related to 
vaccination. This SAE consisted of a day case hospital admission 
11 months after vaccination for arthroscopy, following a knee 
injury sustained six months after vaccination.
Group 2. All subjects developed a local reaction (erythema 
and induration) following vaccination with MVA85A, consistent 
with previous trials.11,15,16 Most subjects also experienced mild 
vaccine-site tenderness, pruritus and scaling (Table 2). All sys-
temic AEs after MVA85A vaccination in Group 2 were mild.
The proportions of subjects experiencing local reactions after 
FP85A in Group 2 and the diameters of local reactions were 
similar to those in Group 1 (Table 2). Symptoms of feverish-
ness (in the absence of a documented fever) were reported by two 
subjects on the day of vaccination with FP85A (four weeks after 
MVA85A). All other systemic AEs after FP85A vaccination in 
Group 2 were mild. There were no SAEs in Group 2.
Group 3. Local reactions after FP85A vaccination were as 
described above for Groups 1 and 2 (Table 2). All systemic AEs 
after FP85A vaccination in Group 3 were mild.
The peak (day 2) diameters of erythema and induration after 
MVA85A vaccination were larger in Group 3, when MVA85A 
was the second poxvirus vaccination, compared with Group 2, 
when MVA85A was the first poxvirus vaccination (Table 2). 
There was one episode of moderate sleep disturbance four 
days after MVA85A vaccination. All other systemic AEs after 
Table 1. Baseline data
Group Group 1 Group 2 Group 3
Regime Fp85a MVa85a-Fp85a Fp85a-MVa85a
Number enrolled 12 12 7
Number of males 1 (8%) 5 (42%) 3 (43%)
Median age in years (min-max) 25 (21 – 45) 26 (21 - 50) 29 (24 – 47)
Continent of birth: europe 11 (92%) 10 (83%) 7 (100%)
asia 1 (8%) 2 (17%) 0
Median age of BCG vaccine in years (min-max)a 12 (0–18) 13 (2–20) 16.5 (5–37)
Median years since BCG vaccinea 10.5 (8–27) 12 (4–36) 15 (1–39)
Number with visible BCG scar 10 (83%) 8 (67%) 6 (86%)
Pre-enrolment Mantoux: diameter of induration in mm (min-max) 4 (0–12) 2 (0–12) 3 (0–12)
Pre-vaccination IFNγ ELISpot responses to PPD in SFC (min-max) 133 (30–1040) 117 (20–690) 183 (3–1073)
The number of subjects within each group and their relative genders, ages and continents of birth are shown. aFor two subjects in Group 1 and two 
subjects in Group 2, the year of BcG vaccination was unknown.
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Table 2. adverse events
Group 1 2 3
Vaccine Fp85a MVa85a Fp85a Fp85a MVa85a
N 12 12 12 7 7
solicited local aes:
Local erythema, diameter:
12 (100%) 
31 mm (13–39) 
Day 0 (0–1)
12 (100%) 
30 mm (1–48) 
Day 0 (0–1)
12 (100%) 
35 mm (0–66) 
Day 0 (0–0)
7 (100%) 
23 mm (7–39) 
Day 0 (0–0)
7 (100%) 
55 mm (40–100)a 
Day 0 (0–1)
Local induration, diameter:
12 (100%) 
9.5 mm (3–14)b 
Day 0 (0–1)
12 (100%) 
10 mm (1–14) 
Day 0 (0–1)
12 (100%) 
10 mm (0–40) 
Day 0 (0–0)
7 (100%) 
9 mm (5–15)c 
Day 0 (0–6)
7 (100%) 
55 mm (12–100) 
Day 0 (0–0)
Local pruritus
12 (100%) 
Day 5 (1–7)
12 (100%) 
Day 2 (0–5)
10 (83%) 
Day 1 (0–6)
6 (86%) 
Day 3 (2–9)
6 (86%) 
Day 1 (0–4)
Local scaling
12 (100%) 
Day 4 (2–7)
9 (75%) 
Day 4 (1–4)
12 (100%) 
Day 4 (0–6)
7 (100%) 
Day 4 (1–7)
5 (71%) 
Day 4 (1–6)
Local tenderness
10 (83%) 
Day 1 (0–6)
11 (92%) 
Day 1 (0–5)
10 (83%) 
Day 0 (0–2)
5 (71%) 
Day 1 (0–7)
7 (100%) 
Day 0 (0–2)
Local warmth
7 (58%) 
Day 1 (0–6)
9 (75%) 
Day 0 (0–6)
10 (83%) 
Day 0 (0–1)
4 (57%) 
Day 1 (0–6)
7 (100%) 
Day 1 (0–1)
Unsolicited local aes:
scar, diameterd 3 mm (25%), 2–4 4 mm (33%), 2–5 4 mm (33%), 3–4 1 mm (14%), 5 0 mm (0%)
solicited systemic aes:
arthralgia
2 (17%) 
Day 0
2 (17%) 
Days 0&1
3 (25%) 
Day 0 (0–1)
1 (14%) 
Day 3
0 (0%)
Fatigue
6 (50%) 
Day 2 (0–6)
7 (58%) 
Day 0 (0–4)
6 (50%) 
Day 0 (0–2)
3 (43%) 
Day 0 (0–3)
4 (57%) 
Day 1 (0–3)
Documented fever 1 (8%), Day 0 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Felt feverish
1 (8%) 
Day 0
4 (33%) 
Day 0 (0–2)
4 (33%) 
Day 0 (0–0)
1 (14%) 
Day 5
2 (29%) 
Days 1&4
Headache
5 (42%) 
Day 2 (0–6)
7 (58%) 
Day 3 (0–6)
4 (33%) 
Day 0 (0–2)
3 (43%) 
Day 1 (1–2)
4 (57%) 
Day 3 (1–4)
Laboratory 0 (0%) 0 (0%) 1 (8%)e 0 (0%) 2 (29%)f
Lymphadenopathy
1 (8%) 
Day 1
0 (0%)
1 (8%) 
Day 0
2 (29%)
Days 1&3
2 (29%) 
Day 1
Malaise
4 (33%) 
Day 2 (0–6)
5 (42%) 
Day 1 (0–3)
5 (42%) 
Day 0 (0–2)
0 (0%)
3 (43%) 
Day 1 (0–3)
Myalgia
1 (8%) 
Day 0
7 (58%) 
Day 0 (0–2)
3 (25%) 
Day 0 (0–1)
3 (43%) 
Day 1 (1–3)
2 (29%) 
Day 1
Nausea
2 (17%) 
Days 0&3
0 (0%)
2 (17%) 
Days 0&2
0 (0%)
1 (14%) 
Day 2
Unsolicited systemic aes:
coryzal symptoms 1 (8%), Day 2 2 (17%), Day 0 0 (0%) 1 (14%), Day 1 1 (14%), Day 4
sleep disturbance 0 (0%) 0 (0%) 0 (0%)
2 (14%) 
Days 0&2
2 (29%) 
Days 1&4
The numbers of subjects within each group reporting each adverse event and the days of onset of each adverse event are shown. Where three or 
more subjects in a group reported a particular adverse event, the median day of onset is shown, with range in parentheses. The median diameter of 
erythema and induration measured by investigators at day two (time of peak local reaction size) is shown, with range in parentheses. aOne diameter of 
erythema after MVa85a in Group 3 classified severe (source: subject diary card); bOne diameter of induration after Fp85a in Group 1 classified severe 
(source: subject diary card); cFour diameters of induration after MVa85a in Group 3 classified severe (source: investigator measurement); dNo subjects 
reported scarring. all reports of scars were noted by investigators. scars were pink or hypopigmented and non-palpable; epotassium 2.9 mmol/l, Biliru-
bin 30 mmol/l one week post-vaccination; faLT 65 and 56 IU/L respectively one week post-vaccination.
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Group 3 were not boosted by subsequent MVA85A vaccination 
(Fig. 4A and Table 4B). There was a trend toward a negative 
correlation between pre-MVA85A anti-FP9 IgG levels and post-
MVA85A IFNγ ELISpot responses to single pool 85A in Groups 
2 and 3 (Fig. 4B).
IgG Responses to MVA. Anti-MVA IgG levels peaked four 
weeks after MVA85A vaccination in Group 2 and were not 
boosted by subsequent FP85A vaccination, but remained above 
baseline throughout follow-up (Fig. 4 and Table 4B). Anti-MVA 
IgG levels did not increase significantly after FP85A vaccination 
but did increase after subsequent MVA85A vaccination in Group 
3, peaking at week 12 and remaining above baseline until week 
24 (Fig. 4). At the time of MVA85A vaccination, anti-MVA 
IgG levels were similar between Groups 2 and 3. There was a 
trend toward a negative correlation between pre-vaccination anti-
MVA IgG levels and post-MVA85A vaccination IFNγ ELISpot 
responses to single pool 85A (Fig. 4B).
Discussion
This clinical trial provides further evidence for the safety of 
recombinant FP9 and MVA vectored vaccines in a healthy adult 
population. FP85A and MVA85A vaccines were well tolerated 
in all regimes. The frequencies of local and systemic AEs were 
comparable to previous clinical trials evaluating MVA85A vac-
cination and FP9 and MVA-vectored candidate malaria vac-
cines.11,15,16,18,19 Peak local reactions were larger in diameter in 
the FP85A-MVA85A regime in Group 3, compared with when 
MVA85A was the first vaccination. However, as previously 
discussed, this was not associated with increased frequency or 
severity of other local or systemic AEs; local reaction sizes were 
comparable by one week and the group size was small, so the 
cell epitopes were detectable in some, but not all subjects, both 
before and after immunisation in all three groups (Fig. 3A and 
Table 4A). The magnitude of all anti-vector responses in all 
groups were considerably lower than antigen 85A responses using 
cryopreserved peripheral blood mononuclear cells (PBMC, (data 
not shown).
In Group 1, responses to the CD4+ and CD8+epitopes 
increased transiently one week after FP85A vaccination (Fig. 3A).
In Group 2, responses to both epitopes increased after MVA85A 
vaccination and were significantly higher than baseline at week 
four, the time of subsequent FP85A vaccination (Fig. 3A). FP85A 
vaccination did not boost responses to the CD4+ or CD8+ epitopes.
In Group 3, following the transiently increased responses after 
FP85A vaccination at week one, responses were similar to screen-
ing levels before MVA85A vaccination at week four, and were not 
boosted by MVA85A vaccination (Fig. 3A).
There were no correlations between ELISpot responses to 
the CD4+ or CD8+ epitopes before MVA85A vaccination and 
85A-specific ELISpot responses one week after MVA85A vacci-
nation (Fig. 3B).
Insert and Vector-specific IgG levels pre and post-vaccina-
tion. IgG responses to r85A. A small, transient increase in IgG 
responses to recombinant 85A (r85A) was observed after FP85A 
vaccination in Groups 1 and 3 but not after MVA85A vaccination 
in Group 2 (Fig. 4A). Following the subsequent vaccinations in 
Group 2 (FP85A) and Group 3 (MVA85A), anti-r85AIgG levels 
did not increase significantly.
IgG responses to FP9. Anti-FP9 IgG levels increased after vacci-
nation with FP85A in Group 1 (Fig. 4A and Table 4B). In Group 
2, anti-FP9 IgG levels increased after MVA85A vaccination and 
were boosted by FP85A vaccination at week four (Fig. 4A and 
Table 4B). Anti-FP9 IgG levels after FP85A vaccination in 
Table 2. adverse events
Dizziness 1 (8%), Day 0 0 (0%) 0 (0%) 0 (0%) 0 (0%)
axillary pain 1 (8%), Day 4 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Indigestion/ reflux 1 (14%), Day 1 1 (8%), Day 0 0 (0%) 0 (0%) 0 (0%)
Rigor 0 (0%) 0 (0%) 1 (8%), Day 0 0 (0%) 0 (0%)
The numbers of subjects within each group reporting each adverse event and the days of onset of each adverse event are shown. Where three or 
more subjects in a group reported a particular adverse event, the median day of onset is shown, with range in parentheses. The median diameter of 
erythema and induration measured by investigators at day two (time of peak local reaction size) is shown, with range in parentheses. aOne diameter of 
erythema after MVa85a in Group 3 classified severe (source: subject diary card); bOne diameter of induration after Fp85a in Group 1 classified severe 
(source: subject diary card); cFour diameters of induration after MVa85a in Group 3 classified severe (source: investigator measurement); dNo subjects 
reported scarring. all reports of scars were noted by investigators. scars were pink or hypopigmented and non-palpable; epotassium 2.9 mmol/l, Biliru-
bin 30 mmol/l one week post-vaccination; faLT 65 and 56 IU/L respectively one week post-vaccination.
Figure 2 (See opposite page). IFNγ eLIspot responses to 85a and soluble serum cytokines. (A) Longitudinal IFNγ eLIspot responses to the single 
85a peptide pool. each dot represents an individual subjects’ response and median responses are connected by lines. Group 1 = Fp85a vaccination 
week 0; Group 2 = MVa85a vaccination week 0, Fp85a vaccination week four; Group 3 = Fp85a vaccination week 0, MVa85a vaccination week four. 
No increases in responses to antigen 85a were seen after Fp85a vaccination in Group 1. MVa85a vaccination induced strong IFNγ T cell responses to 
antigen 85a in Group 2, which were maintained throughout the 52 week follow up, but were not boosted by subsequent Fp85a vaccination at week 
four. There were no responses after Fp85a vaccination in Group 3, but subsequent MVa85a vaccination at week four induced moderate IFNγ T cell 
responses to antigen 85a. (B) proportion of subjects with detectable soluble serum cytokines. The bars show the proportion of subjects within each 
group, in whose serum, any cytokines were detectable. Group 1 = Fp85a vaccination week 0; Group 2 = MVa85a vaccination week 0, Fp85a vac-
cination week four; Group 3 = Fp85a vaccination week 0, MVa85a vaccination week four; days = days since enrolment. serum IFNγ and TNFα were 
detected in no more than one subject’s serum at any one time point. IL-8 was detected in all Group 2 subjects’ serum by day seven (one week after 
MVa85a vaccination).
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MVA85A, but not FP85A vaccination induced strong 
85A-specific cellular immunity. FP85A vaccination did not 
boost the responses to prior MVA85A vaccination (Group 2) and 
responses to MVA85A vaccination were inhibited by prior FP85A 
significance is uncertain.20 All other local and systemic AEs in 
these subjects were mild and AEs were otherwise comparable 
between groups, as observed in previous clinical trials of FP9 and 
MVA vectored candidate malaria vaccines.19
Figure 2. For figure legend, see page 54.
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vector was immunologically active. Positive and negative controls 
excluded technical problems with the assays and results were 
reproduced using frozen samples.
Serum was evaluated for the presence of the Th1 cytokines 
IFNγ and TNFα. The chemokine IL-8 was also measured because 
microarray analysis has previously demonstrated IL-8 to be one of 
the genes induced by MVA-infection of a cell.24 We speculate that 
IL-8 may be one of the mediators involved in directing the magni-
tude of the antigen-specific response to MVA85A. IL-8 is released 
by macrophages in response to M.tb components, is chemotactic to 
neutrophils and thought to be important in granuloma formation 
and protection against disease.25,26 It would be interesting to evalu-
ate further the role of IL-8 in early innate and adaptive cellular 
immune responses to MVA85A vaccination.
We used cryopreserved PBMC to investigate the inhibi-
tory effect of prior vaccination with FP85A on the antigen-
specific response to MVA85A vaccination. CD4+ and CD8+ T 
cell responses were detected upon stimulation of PBMC with 
Vaccinia epitopes following MVA85A vaccination in Group 2, 
but not in Group 3. No cell-mediated responses to Vaccinia epi-
topes were detected following FP85A vaccination. We therefore 
examined the serum IgG responses to MVA and FP9. Anti-MVA 
IgG antibodies were detected following MVA85A vaccination, 
vaccination (Group 3). The same trend was observed in analysis 
of soluble cytokines, with IL-8 detected after MVA85A vaccina-
tion in Group 2 but not in Group 3.
Recombinant FP9-vectored vaccines induce weaker immune 
responses than recombinant MVA vaccines and MVA85A elic-
its unusually high responses compared with other recombinant 
MVA vaccines.11,13,15,16,21-23 In malaria vaccine clinical trials with a 
number of different antigen inserts, an increased IFNγ response 
compared with baseline was seen in FP9-MVA regimes with a 
similar interval between vaccinations with different viral vec-
tors.6,18 Given the strong immune responses to MVA85A vaccina-
tion, we would expect at least modest antigen-specific immune 
responses following vaccination with FP85A.
Identity polymerase chain reaction (PCR) and sequencing 
assays had confirmed the presence of the 85A insert within the 
FP9 vector and no wild type FP9 was present. The clinical grade 
FP85A vaccine also passed annual murine potency assays, involv-
ing evaluation for antigen-specific cellular immune responses, 
which were lower for FP85A than MVA85A (data not shown). 
The antigen insert was therefore both present within the recom-
binant vector and recognizable by the adaptive immune system. 
In the clinical trial, FP85A induced local and systemic reactions 
typical of poxviruses, providing additional evidence that the viral 
Table 3. statistics for IFNγ eLIspot responses to antigen 85a
3A: Comparison of responses to single 85A pool within groups using Wilcoxon signed rank test
Group Vaccine Baseline responseab Peak responseac Median difference (range) p value
1 FP85A (week 0) 10 (0–83) 5 (0–70) 0 (0–16) 0.30
2 MVA85A (week 0) 7 (0–113) 1270 (430–1660) 1234 (430–1660) 0.002
FP85A (week 4) 415 (90–1623) 357 (113–577) -192 (-1140–130) 0.02
3 FP85A (week 0) 7 (0–43) 17 (0–93) 10 (0–73) 0.07
MVA85A (week 4) 3 (0–47) 87 (17–353) 54 (3–313) 0.02
3B: Comparison of 85A specific responses to MVA85A between groups using Mann Whitney U test
Group 2 (n = 12)a Group 3 (n = 7)a Difference in medians (95% CI) p value
AUC 8560 (2458–28797) 1110 (146–1341) 7816 (3100–18437) < 0.001
Peak (one week after 
MVA85A vaccination)
1270 (430–1660) 87 (17–353) 1085 (557–1573) < 0.001
Plateau (week 52) 85 (17–630) 20 (3–57) 60 (14–270) 0.01
cellular IFNγ secretion by pBMc in response to antigen 85a stimulation was evaluated using eLIspot assays to determine the number of spot forming 
cells (sFc). post-vaccination responses were compared with baseline pre-vaccination responses using a paired analysis (Table 3A) and responses be-
tween groups were also compared (Table 3B). aMedian IFNγ eLIspot responses to a single pool of 85a peptides are shown, with range in parentheses 
(units: sFc per million pBMc); bBaseline responses were taken before vaccination (for the second vaccine in Groups 2 and 3, baseline responses shown 
are from week four); cpeak responses are one week after vaccination.
Figure 3 (See opposite page). IFNγ eLIspot responses to Vaccinia cD4+ and cD8+ T cell epitopes. (A) Longitudinal IFNγ eLIspot responses to known 
Vaccinia cD4 and cD8 epitopes each dot represents an individual subjects’ response and median responses are connected by lines. Group 1 = Fp85a 
vaccination week 0; Group 2 = MVa85a vaccination week 0, Fp85a vaccination week four; Group 3 = Fp85a vaccination week 0, MVa85a vaccina-
tion week four. Minimal, transient increases in Vaccinia cD8+ responses compared with baseline were observed after Fp85a vaccination in Group 1. 
Transient responses to Vaccinia cD4+ and cD8+ epitopes were observed after MVa85a, but not Fp85a vaccination in Group 2. In Group 3, responses 
to Vaccinia epitopes did not significantly increase after either Fp85a or MVa85a vaccinations. (B) correlation between IFNγ eLIspot responses to 
Vaccinia cD4+ and cD8+ at the time of MVa85a vaccination and IFNγ eLIspot responses to antigen 85a one week after MVa85a vaccination. each dot 
represents an individual subjects’ responses. pre-vaccination responses were from the day of MVa85a vaccination (Group 2 = week 0; Group 3 = week 
four). post-vaccination responses were from samples taken one week after MVa5a vaccination (Group 2 = week one; Group 3 = week five). circles = re-
sponses to Vaccinia cD4+ epitopes; diamonds = responses to Vaccinia cD8+ epitopes. No relationship between pre-vaccination anti-vector responses 
(y axes) and post-vaccination T cell responses (x axes) for MVa85a vaccination was found.
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Figure 3. For figure legend, see page 56.
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with MVA85A may be one factor mediating the inhibition of 
antigen-specific cellular immune responses to vaccination with 
MVA85A.
Materials and Methods
Study design. This was an open label, non-randomized, Phase 
I safety and immunogenicity clinical trial in healthy, previously 
BCG-vaccinated, adult subjects.
but not after FP85A vaccination. Anti-FP9 IgG levels increased 
after MVA85A vaccination as well as after FP85A vaccination, 
suggesting anti-FP9 IgG is cross-reactive for MVA85A.
In conclusion, FP85A vaccination was safe and well tolerated 
in healthy adults. However, unlike MVA85A vaccination, FP85A 
vaccination did not increase 85A-specific immune responses. 
FP85A vaccination inhibited the antigen-specific and vector-spe-
cific cellular responses to subsequent MVA85A vaccination. We 
speculate that anti-FP9 IgG antibodies which are cross-reactive 
Table 4. anti-vector IFNγ eLIspot and eLIsa statistics
4A: Comparison of cellular anti-vector responses within groups using Wilcoxon signed rank test
Vaccinia epitopes Group Vaccine Pre-vaccinationab Post-vaccinationac Median difference (range) p value
CD4+ 1 FP85A (week 0) 0 (0–20) 8 (0–25) 4 (-10–20) 0.06
2 MVA85A (week 0) 8 (0–28) 13 (0–100) 3 (-10–90) 0.12
FP85A (week 4) 19 (0–48) 14 (2–43) -6 (-38–20) 0.50
3 FP85A (week 0) 5 (2–20) 15 (0–27) 1 (-3–10) 0.14
MVA85A (week 4) 8 (0–22) 5 (0–15) -3 (-19–13) 0.50
CD8+ 1 FP85A (week 0) 0 (0–7) 3 (0–13) 3 (-7–13) 0.04
2 MVA85A (week 0) 3 (0–12) 10 (0–67) 5 (0–64) 0.003
FP85A (week 4) 9 (0–40) 10 (2–38) -1 (-5–31) 0.66
3 FP85A (week 0) 2 (0–18) 3 (0–18) 1 (0–5) 0.05
MVA85A (week 4) 3 (0–18) 3 (0–8) 0 (-13–6) 0.73
4B: Comparison of humoral anti-vector immune responses within groups using Wilcoxon signed rank test
IgG Group Vaccine Pre-vaccinationab Post-vaccinationac Median difference (range) p value
FP9 1 FP85A (week 0) 0.15 (0.12–0.26) 0.36 (0.19–0.50) 0.17 (0.06–0.36) 0.002
2 MVA85A (week 0) 0.23 (0.15–0.42) 0.32 (0.09–0.61) 0.08 (-0.13–0.37) 0.02
FP85A (week 4) 0.32 (0.09–0.61) 0.41 (0.23–0.74) 0.11 (-0.16–0.36) 0.02
3 FP85A (week 0) 0.20 (0.12–0.31) 0.34 (0.19–1.11) 0.08 (0.03–0.95) 0.02
MVA85A (week 4) 0. 34 (0.19–1.11) 0.35 (0.19–0.85) 0.01 (-0.27–0.05) 0.74
MVA 1 FP85A (week 0) 0.16 (0.11–0.72) 0.19 (0.13–0.70) 0.01 (-0.19–0.14) 0.24
2 MVA85A (week 0) 0.17 (0.11–0.58) 0.66 (0.30–1.36) 0.49 (0.12–1.19) 0.002
FP85A (week 4) 0.66 (0.30–1.36) 0.53 (0.30–1.20) -0.08 (-0.36–0.06) 0.03
3 FP85A (week 0) 0.21 (0.16–0.61) 0.21 (0.16–0.57) 0.00 (-0.05–0.11) 0.74
MVA85A (week 4) 0.21 (0.16–0.57) 0.54 (0.26–1.18) 0.08 (0.61–2.37) 0.02
cellular IFNγ secretion by pBMc in response to stimulation with Vaccinia cD4+ and cD8+ epitopes was evaluated using eLIspot assays to determine the 
number of spot forming cells (sFc) (Table 4A). serum IgG responses to Fp9 and MVa were evaluated by eLIsa (Table 4B). post-vaccination responses 
were compared with baseline pre-vaccination responses using a paired analysis. (Table 4A) aMedian IFNγ eLIspot responses to Vaccinia cD4+ and cD8+ 
epitopes are shown, with range in parentheses (units: sFc per million pBMc); bpre-vaccination responses shown are from week four for the second vac-
cine in Group 2 and 3; cpost-vaccination responses shown are one week after each vaccine. (Table 4B) aMedian serum IgG levels are shown, with range 
in parentheses (units: OD); bpre-vaccination responses shown are from week four for the second vaccine in Group 2 and 3; cpost-vaccination responses 
shown are four weeks after the first vaccine Groups 1, 2 and 3, and eight weeks after the second vaccine in Groups 2 and 3.
Figure 4 (See opposite page). serum IgG eLIsa responses to r85a, MVa and Fp9. (A) Longitudinal r85a IgG, Fp9 IgG and MVa IgG responses detected 
by eLIsa each dot represents an individual subjects’ response and median responses are connected by lines. Group 1 = Fp85a vaccination week 0; 
Group 2 = MVa85a vaccination week 0, Fp85a vaccination week four; Group 3 = Fp85a vaccination week 0, MVa85a vaccination week four. anti-vector 
antibody responses were generally stronger than antigen-specific anti-85a IgG responses. In Group 1, Fp85a vaccination induced an Fp9 IgG response, 
but no MVa IgG antibodies. In Group 2, MVa85a vaccination induced Fp9 IgG and MVa IgG responses. subsequent Fp85a vaccination boosted the Fp9 
IgG response but did not boost the MVa IgG response. In Group 3, MVa85a vaccination induced an MVa IgG response, but did not boost the Fp9 IgG 
response to prior Fp85a vaccination. (B) correlation between Fp9 IgG and MVa IgG levels detectable by eLIsa at the time of MVa85a vaccination and 
IFNγ eLIspot responses to antigen 85a one week after MVa85a vaccination. each dot represents an individual subjects’ responses. pre-vaccination re-
sponses were from the day of MVa85a vaccination (Group 2 = week 0; Group 3 = week four). post-vaccination responses were from samples taken after 
MVa5a vaccination (Group 2 = week four; Group 3 = week 12). circles = Fp9 IgG levels; diamonds = MVa IgG levels. There were trends toward negative 
correlations between pre-MVa85a Fp9 and MVa IgG levels and post-MVa85a IFNγ eLIspot responses to single pool 85a in Groups 2 and 3.
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(full blood count), or biochemistry (sodium, potassium, cre-
atinine, urea, albumin, bilirubin, Alkaline Phosphatase and 
Alanine aminotransferase) tests. Exclusion criteria were evidence 
of latent M.tb infection (LTBI) by Mantoux reaction (diameter 
Participants. Subjects were recruited from the Oxford region 
in the UK. Inclusion criteria were healthy adults; aged 18–50; 
BCG-vaccinated; seronegative for HIV, hepatitis B and hepatitis 
C viruses; no clinically significant abnormalities in hematology 
Figure 4. For figure legend, see page 58.
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screening and weeks one and 12 for all groups and additionally at 
week four for Groups 2 and 3. Solicited and unsolicited AEs were 
recorded by investigators in case report forms at each follow up 
appointment. The criteria for assigning AE severity and causality 
have been described previously.20 All AEs deemed possibly, prob-
ably or definitely related to vaccination have been reported. The 
transverse diameters of erythema and induration (palpable hard-
ening of skin) were measured by clinically qualified and trained 
investigators two and seven days after each vaccination and four, 
eight, 12, 24 and 52 weeks after enrolment.
Immunological assays. Blood samples for exploratory immu-
nology analyses were taken at screening and two days after vac-
cination and weeks one, four, eight, 12, 24 and 52 for all groups 
and additionally at week five for Groups 2 and 3. At each time 
point except day two, 50 ml lithium-heparinized blood and five 
ml serum sample were taken. A maximum of 20 ml blood was 
taken two days after vaccination. PBMC were extracted from 
lithium heparinized blood as previously described.11
ELISpot assays. The principal readout for evaluating vaccine-
induced cellular immunogenicity was by ex-vivo IFNγ ELISpot 
assay using fresh PBMC as previously described.8,11 The antigens 
used were seven pools of antigen 85A peptides; a single pool of 
all 66 85A peptides; r85A; purified protein derivative (PPD) 
as described.8,11 For detection of LTBI at screening, wells were 
plated with ESAT-6 and CFP-10 peptides as described.11
Anti-vector IFNγ ELISpot was performed using frozen 
PBMCs, stored in liquid nitrogen. Cells were flash thawed at 
37°C, resuspended in R10 and centrifuged at 1400 rpm for seven 
minutes. All samples had a viability of greater than 95%. Cells 
were rested overnight at 37°C, 5% CO
2
 in R10 containing 10U/
ml of Benzonase (Novagen) at 1 × 106 PBMC/ml. They were 
then washed and plated according to the ELISpot protocol.
Anti-vector IFNγ responses were mapped to CD4+ (27 pep-
tides) and CD8+ (36 peptides) T cell epitopes present in Vaccinia 
and MVA (Table S1). Peptides were synthesized according to 
the sequences obtained from published literature.31-37 As these 
assays were performed on frozen cells, all samples were also re-
tested with the 85A single 66-peptide pool. All ELISpot assays 
included unstimulated cells as a negative control and 10μg/ml 
Staphylococcal enterotoxin B (SEB, Sigma) as a positive control.
Detection of soluble cytokines. Serum samples from enrolled 
subjects were evaluated for the presence of soluble cytokines 
IFNγ, TNFα and IL-8. Frozen serum samples from screening 
and days two and seven were thawed at room temperature. To 
each FlowCytomix reaction, 25 μL of serum was added, and the 
assay performed according to the manufacturer’s instructions 
(FlowCytomix Basic kit and Simplex kits for IL-8, TNFα and 
IFNγ, Bender MedSystems). The cytokine-bound beads were 
detected on a Beckman Coulter CyAN flow cytometer and the 
results analyzed using the Bender MedSystems Flow Cytomix 
Pro 2.3 software.
IgG enzyme linked immunosorbent assay (ELISA). IgG 
was measured in serum samples, tested in duplicate. NUNC 
Immuno Plates (Fisher) were coated with r85A (5 μg/ml); FP9 (5 
× 105 pfu/well); or MVA (5x105 pfu/well) in 0.05 M carbonate-
bicarbonate buffer and incubated overnight at 4°C. Plates were 
greater than 15 mm) or IFNγ ELISpot responses to M.tb-specific 
antigens ESAT-6 or CFP-10. Mantoux tests were performed by 
clinically qualified investigators according to national guide-
lines.27 Females entering the study were required to have a nega-
tive pregnancy test and plans for reliable contraception for the 
duration of inclusion.
Ethics. This study was approved by the Medicines and 
Healthcare products Regulatory Agency (MHRA) and con-
ducted in accordance with the Declaration of Helsinki. Ethical 
approval was obtained from the Gene Therapy Advisory 
Committee (GTAC) and Site Specific Assessment performed 
by the Oxfordshire Research Ethics Committee (OxRecA). 
Written informed consent was obtained from all subjects prior 
to participation.
Interventions. Interventions were two candidate TB vaccines, 
FP85A and MVA85A. FP85A is a recombinant FP9 vector encod-
ing antigen 85A. FP9 is a fully sequenced, live, highly attenuated 
form of a European strain of Fowlpox virus, derived by multiple 
passages of the wild-type Fowlpox virus in avian cells.28 FP85A 
was constructed using an established protocol.29 The 85A DNA 
sequence (derived from M.tb H37Rv) was ligated into the unique 
SmaI cloning site of the Fowlpox shuttle vector pEFL29, plac-
ing gene expression under the control of the Vaccinia virus P7.5 
promoter. Recombinant viruses were prepared by in vitro recom-
bination of the shuttle vector encoding 85A with FP9 in primary 
cultures of chicken embryo fibroblasts (CEFs) and selected by 
repeated plaque purification in CEF monolayers. The MVA85A 
vaccine was constructed as previously described.30
Clinical grade MVA85A and FP85A vaccines were pro-
duced under Good Manufacturing Practice conditions by IDT 
Biologika GmbH (Dessau-Rosslau, Germany).
All vaccine doses were 5 × 107 plaque forming units (pfu) 
administered by intradermal injection into the deltoid area of the 
arm. The volumes of vaccine administered were 70 μl (FP85A) 
or 135 μl (MVA85A). In Group 1, the vaccine was administered 
into the opposite arm compared with BCG. In Groups 2 and 3, 
where two vaccines were administered with a four week interval, 
vaccines were injected into opposite arms.
Sample size. The planned sample size was 36 subjects, with 
12 subjects in each group, aiming to detect frequently occurring 
AEs. Sample size calculations were performed using Stata 9 and 
12 subjects per group gave a 90% power to detect a 40% differ-
ence in immune responses between two groups.
Enrolment. Subjects were allocated into three groups sequen-
tially, in order of enrolment. Subjects in Group 1 were vaccinated 
with FP85A at enrolment. An interim safety analysis of FP85A 
vaccination was performed before enrolling subjects into Groups 
2 and 3. Subjects in Group 2 were vaccinated with MVA85A at 
enrolment and FP85A at week four. Subjects in Group 3 were 
vaccinated with FP85A at enrolment and MVA85A at week 
four. Subjects were followed up regularly for one year following 
enrolment.
Safety analysis. Daily diary cards recording local and systemic 
AEs, local reaction sizes and body temperature were completed 
by subjects for seven days following each vaccination. Blood 
samples for hematology and biochemistry analysis were taken at 
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using the Wilcoxon signed-rank test. The relationship between 
pre-vaccination anti-vector cellular and antibody responses and 
vaccine-induced cellular immune responses was evaluated by cal-
culating rank correlation coefficient (Spearman’s rho, Stata).
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washed in PBS/Tween20 and blocked with 1% Casein in PBS 
(Fisher Scientific) for one hour, before the addition of serum, 
diluted 1:50 (r85A plates) or 1:100 (viral plates) in Casein. Plates 
containing serum were incubated for one hour and washed five 
times with PBS/Tween. Goat anti-human IgG alkaline phospha-
tase secondary antibody (Sigma) was added and plates incubated 
for one hour, and washed five times. Plates were developed by add-
ing 50μl of Diethanolamine buffer (Fisher) with 4-Nitrophenyl 
Phosphate tablet (Sigma) according to manufacturer’s recom-
mendation and read at 13 min (r85A plates) or seven minutes 
(viral plates), timed from the beginning of the addition of devel-
oping buffer.
Statistical analysis. Post-vaccination responses to each stimu-
lating antigen within each regime were compared with pre-vacci-
nation (baseline) responses using the Wilcoxon signed-rank test 
(Stata Statistical Software, Release 9.0, 2005). Non-parametric 
tests were used as the data were not normally distributed.
The overall magnitude of vaccine-induced IFNγ T cell 
ELISpot responses was summarized using the area under the 
curve (AUC) for each stimulating antigen and regime after sub-
tracting pre-vaccination responses (Stata). AUC responses were 
compared between groups using the Mann Whitney U test. 
Where differences in AUC between groups were detected, peak 
(week one) and plateau (week 52) responses were compared, 
using the Mann-Whitney U test.
Post-vaccination anti-vector cellular and humoral responses 
within each group were compared with pre-vaccination responses 
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